Ekso Bionics Holdings Inc 2026年季度报告

FORM10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended March 31, 2026 or ☐TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from ______ to ______ Commission File Number: 001-37854 Ekso Bionics Holdings,Inc. (Exact name of registrant as specified in its charter) (Stateorotherjurisdictionofincorporationororganization)(I.R.S.EmployerIdentificationNo.) (Addressofprincipalexecutiveoffices) (Registrant’s telephone number, including area code) (Former name, former address, and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Name of each exchange on which registered: Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon Stock, $0.001 par value per shareEKSONasdaq Capital Market Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2)has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒Emerging growth company☐ Large accelerated filer☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).Yes☐No☒ The number of shares of registrant’s common stock outstanding as ofApril 27, 2026 was 3,563,381. Ekso Bionics Holdings,Inc. Quarterly Report on Form10-Q Table of Contents PARTI. FINANCIAL INFORMATIONItem 1.Financial Statements4Condensed Consolidated Balance Sheets as of March 31, 2026(unaudited) and December31, 20254Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months endedMarch 31, 2026and2025(unaudited)5Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity for the ThreeMonths ended March31, 2026and 2025(unaudited)6Condensed Consolidated Statements of Cash Flows for the Three Months ended March 31, 2026and2025(unaudited)8Notes to Condensed Consolidated Financial Statements (unaudited)9Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations29Item 3.Quantitative and Qualitative Disclosures About Market Risk37Item 4.Controls and Procedures37PARTII. OTHER INFORMATIONItem 1.Legal Proceedings38Item 1A.Risk Factors38Item 5.Other Information41Item 6.Exhibits42Signatures43 Ekso Bionics Holdings, Inc.Condensed Consolidated Balance Sheets(In thousands, except par value) Ekso Bionics Holdings, Inc.Condensed Consolidated Statements of Operations and Comprehensive Loss(In thousands, except per share amounts)(Unaudited) Three Months EndedMarch 31,20262025Revenue$2,141$3,375Cost of revenue1,0671,569Gross profit1,0741,806 Ekso Bionics Holdings, Inc.Condensed Consolidated Statements of Cash Flows(In thousands)(Unaudited) Ekso Bionics Holdings, Inc.Notes to Condensed Consolidated Financial Statements($ and share amounts in thousands, except per share amounts)(Unaudited) 1.Organization Description of Business EksoBionics Holdings,Inc.(the“Company”)designs,develops,and markets exoskeleton and complementary productsthataugment human strength, endurance and mobility. The primary end market for our exoskeleton technology is healthcare, whereour technology primarily serves people with physical disabilities or impairments in both physical rehabilitation and mobility.TheCompany has marketed devices that (i) enable individuals with neurological conditions affecting gait, including acquired braininjury("ABI")and multiple sclerosis("MS"),and spinal cord injury("SCI")to rehabilitate and to stand and walk inneurorehabilitation settings and, for patients with a SCI, for home and community use, (ii) assist individuals with a broad range ofupper extremity impairments, and (iii) allow industrial workers to perform difficult repetitive work for ex